The development of multitarget compounds against multifactorial diseases, such as Alzheimer's disease, is an area of very intensive research, due to the expected superior therapeutic efficacy that should arise from the simultaneous modulation of several key targets of the complex pathological network. Here we describe the synthesis and multitarget biological profiling of a new class of compounds designed by molecular hybridization of an NMDA receptor antagonist fluorobenzohomoadamantanamine with the potent acetylcholinesterase (AChE) inhibitor 6-chlorotacrine, using two different linker lengths and linkage positions, to preserve or not the memantine-like polycyclic unsubstituted primary amine. The best hybrids exhibit greater potencies than parent compounds against AChE (IC50 0.33 nM in the best case, 44-fold increased potency over 6-chlorotacrine), butyrylcholinesterase (IC50 21 nM in the best case, 24-fold increased potency over 6-chlorotacrine), and NMDA receptors (IC50 0.89 µM in the best case, 2-fold increased potency over the parent benzohomoadamantanamine and memantine), which suggests an additive effect of both pharmacophoric moieties in the interaction with the primary targets. Moreover, most of these compounds have been predicted to be brain permeable. This set of biological properties makes them promising leads for further anti-Alzheimer drug development.
Introduction
Alzheimer's disease (AD) is a chronic neurodegenerative disorder that causes cognitive impairment and inexorably leads to dementia and death. With age being the main risk factor, the societal burden of AD in an increasingly aging population is reaching alarming proportions worldwide. The most worrisome predictions about AD prevalence, mortality, and associated economic costs are being continuously exceeded [1], thereby putting health systems and national economies at unmanageable risk if current drug discovery efforts do not result in efficacious treatments.
Only four drugs are currently used for AD treatment, namely the acetylcholinesterase (AChE) inhibitors donepezil, galantamine, and rivastigmine, and the glutamate NMDA receptor antagonist memantine. These drugs address the marked impairment in neurotransmitter systems, prominently the cholinergic and the glutamatergic system that occur in AD patients as a consequence of synaptic dysfunction and neuronal death, which is one of the main histopathological hallmarks of AD. Other two common features are senile plaques and neurofibrillary tangles, which result from overproduction and aggregation of β-amyloid peptide (Aβ) and hyperphosphorylation and aggregation of tau protein, respectively. Despite some evidence of disease-modifying effects by the currently approved anti-Alzheimer drugs [2] [3] [4] [5] [6] [7] , they are regarded and used as symptomatic drugs. Since the launching of these drugs, research efforts have pursued the development of alternative neurotransmitter-based symptomatic therapies and, mainly, new drugs that act specifically on a given biological target or event with a prominent pathogenic role, in most cases related to Aβ and tau biology. Unfortunately, the enormous amounts of research efforts and resources that have been invested in the past three decades have not been corresponded by the discovery of novel drugs that have proven capable of halting or even just slowing down the neurodegenerative processes occurring in this fatal disease. Indeed, AD is one of the therapeutic areas with the highest attrition rates in clinical trials [8, 9] . Very disappointingly, no drug candidate has successfully passed phase III clinical trials for AD since the launching of memantine, almost two decades ago.
The repetitive failures of very promising target-specific drugs in clinical trials is leading to a growing awareness of the complex multifactorial nature of AD, which could result from the dysregulation of multiple separate but integrated signaling pathways. A scenario of a complex pathogenic network would account for the lack of efficacy of drugs that address a particular signaling pathway by modulation of a single biological target, and warrants the development of alternative therapeutic approaches based on the simultaneous modulation of several crucial biological targets, which should result in additive or synergistic effects [10, 11] . Multitarget treatments may involve the use of several specific drugs (drug cocktails or fixed-dose combinations) or a single drug with the ability to hit several biological targets (multitarget drugs). Even though the design and development of multitarget drugs can be very challenging [12] , it has some clear advantages over multiple-medication therapies, such as simpler dose regimens and improved patient compliance, simpler pharmacokinetics and lack of drug-drug interactions, and simpler clinical development, among others [13, 14] . In fact, both strategies are being currently used in AD treatment or pursued in AD drug discovery.
On the one hand, the combination of the AChE inhibitor donepezil with the glutamate NMDA antagonist memantine has proven to lead to additive or synergistic effects in mouse models and AD patients [15] [16] [17] , and a fixed-dose combination of both drugs (Namzaric®) is now being used as the standard of care to treat dementia associated with moderate to severe stages of the disease [18, 19] . On the other hand, AD is one of the therapeutic areas where the development of multitarget drugs has been more intensively pursued in the past decade [20] [21] [22] . Most of these compounds are hybrids that combine distinct pharmacophoric moieties to confer multiple activities [for recent examples see [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . A crucial point in the design of multitarget anti-Alzheimer compounds is the selection of the biological targets to hit, and, hence, of the pharmacophores to be used.
Many different combinations of targets have been considered, with most of them including AChE. Particularly, the mechanism of action of the currently marketed anti-Alzheimer drugs and the fact that the combination of both mechanisms in the fixed-dose combination of an AChE inhibitor (donepezil) and a glutamate NMDA receptor antagonist (memantine) results in improved clinical efficacy have provided a valuable clue for the design of hybrid compounds that combine pharmacophoric moieties to impart those activities [38] [39] [40] . Some of these compounds feature a moiety of a wellknown AChE inhibitor, such as galantamine or 7-methoxytacrine [41] , linked through an oligomethylene tether to a memantine or the closely related amantadine unit (compounds 3-5, Figure 1 ) [42] [43] [44] [45] . These compounds exhibit nanomolar to submicromolar AChE inhibitory activities and low micromolar affinities towards glutamate NMDA receptors, slightly lower than that of memantine. Very interestingly, one of them, ARN14140, gave cognition enhancing effects and balanced the levels of biomarkers of neurodegeneration, synaptic plasticity, and apoptosis in a non-transgenic 5 mouse model of AD [43] , thereby highlighting the therapeutic potential of the combination of AChE inhibition and NMDA receptor antagonism in a single multitarget molecule. During the past decade we have been exploring the glutamate NMDA receptor antagonistic activity of novel polycyclic amines featuring oxaadamantane [46] , noradamantane and bisnoradamantane [47] , benzohomooxaadamantane [48] , and benzohomoadamantane [49, 50] scaffolds, as bioisosteric, ring-contracted or ringexpanded analogs of memantine. Among these compounds, the fluorobenzohomoadamantanamine 6 ( Figure 2 ) and its non-fluorinated analog turned out to be the most potent NMDA receptor antagonists, with potencies very close to that of memantine in a functional assay in rat cultured cerebellar granule neurons (CGN) [50] . The proven therapeutic potential of the combination of glutamate NMDA receptor antagonism with AChE inhibition, the interesting NMDA antagonistic activity of the benzohomoadamantanamine 6, and our own experience in the development of multitarget anti-Alzheimer compounds containing AChE inhibitor pharmacophores [51] [52] [53] [54] prompted us to undertake the design of a novel class of multitarget hybrid compounds featuring the aminopolycyclic scaffold of 6 and a unit of the potent AChE inhibitor 6-chlorotacrine [55] ( Figure 2 ). In all memantine-or amantadine-based multitarget hybrids previously reported, the aminopolycyclic moiety is linked to the AChE inhibitor moiety through the amino group. It has been reported that alkylation (monomethylation) of the amino group of memantine leads to a twofold decrease of affinity and antagonistic activity towards NMDA receptors, whereas dialkylation has a much more dramatic effect (3-fold reduced affinity and 12-fold reduced NMDA antagonistic activity) [56] . This trend was also observed in some of the polycyclic amines we had developed as NMDA receptor antagonists [47, 49, 50] , but not in all of them [46, 48] . To further shed light on this, we envisaged the synthesis of two short series of benzohomoadamantane-chlorotacrine hybrids, where the attachment point of the aminopolycyclic moiety to the rest of the molecule was either the bridgehead aliphatic primary amino group or a second amino group placed at the benzene ring, 7 thereby leaving unsubstituted the "memantine-like" aliphatic amino group ( Figure 2) . A linker length similar to that used in the previously reported memantine-or amantadinebased multitarget compounds was envisaged for the novel benzohomoadamantanechlorotacrine hybrids.
Here we report the synthesis of this novel class of benzohomoadamantane-chlorotacrine hybrids and their in vitro biological profiling, including the determination of their inhibitory activity against both human cholinesterases (human AChE (hAChE) and human butyrylcholinesterase (hBChE)), glutamate NMDA receptor antagonistic activity, and brain permeability. Because other families of 6-chlorotacrine-related hybrids developed in our group have shown activity against the enzyme BACE-1 (βsecretase) and Aβ42 and tau aggregation [51] [52] [53] [54] , the novel benzohomoadamantanechlorotacrine hybrids were also evaluated against these other targets of interest in AD treatment.
Results and discussion

Synthesis of the novel benzohomoadamantane-chlorotacrine hybrids
The synthesis of the target hybrids 13a and 13b, in which the benzohomoadamantanamine moiety was linked throught its primary amino group to the chlorotacrine unit, was carried out by the alternative sequences depicted in Scheme 1, using 6-chlorotacrine, 7 [55] , or the dichloroacridine derivative 8 [57] as the starting materials. We initially envisaged a four-step route that involved alkylation of 6chlorotacrine with the appropriate ω-bromoalkanenitrile, followed by hydrolysis of the cyano group, amide coupling of the resulting carboxylic acid with the benzohomoadamantanamine 6, and final reduction of the amide to the secondary amine. Alkaline hydrolysis of nitriles 11a and 11b, followed by acidification with an Et2O solution of HCl afforded the corresponding carboxylic acids, in the form of quinoline hydrochloride salts, which were directly coupled with amine 6 using EDC and HOBt, to yield amides 12a and 12b in moderate yields (40% and 75% overall), after silica gel column chromatography purification. Reduction of amides 12a and 12b to the corresponding secondary amines turned out to be a difficult task. Different attempts of reduction with LiAlH4, LiBH4, or sodium bis(2-methoxyethoxy)aluminium hydride (Red-Al®) were fruitless. Finally, borane reduction of amides 12a and 12b did afford the target amines 13a and 13b, albeit in low yield (24% and 10%, respectively).
Alternatively, amine 13b was obtained by alkylation of amine 6 with mesylate 10b, which was prepared by amination of chloroquinoline 8 with 5-amino-1-pentanol at 135 ºC, followed by mesylation of the resulting alcohol 9b. Under these conditions, 13b was obtained in higher yield (27%) but it was accompanied with some byproducts arising from degradation of the mesylate. All the benzohomoadamantane-chlorotacrine hybrids were converted into the corresponding hydrochloride or dihydrochloride salts by treatment with HCl / MeOH, prior to their chemical characterization and biological profiling.
Acetylcholinesterase and butyrylcholinesterase inhibition by the novel benzohomoadamantane-chlorotacrine hybrids
Apart from AChE, the enzyme BChE is in part responsible for the hydrolysis of the neurotransmitter acetylcholine (ACh) in the central nervous system (CNS), thereby contributing to the cholinergic deficit characteristic of AD patients. This is especially true in advanced stages of the disease, in which the levels of AChE are markedly decreased, whereas the levels of BChE remain the same or even increase, thereby acquiring a prominent role in ACh breakdown [60] . Thus, BChE inhibition or even (Table 1) . All the novel hybrids turned out to be highly potent hAChE inhibitors, with IC50 values from subnanomolar (18a: 0.33 nM) to 2.5 nM (Table 1) . Thus, the benzohomoadamantane-chlorotacrine hybrids are clearly more potent hAChE inhibitors (6-44-fold more potent) than the parent 6-chlorotacrine, 7, which is indicative of an additive or synergistic effect by the benzohomoadamantane moiety and/or the linker. In the first series, with IC50 values in the very narrow range of 1.30-1.96 nM, neither the linker length nor the presence of an amide or an amine as the attachment functionality to the benzohomoadamantane core seems to play a differential role in hAChE inhibition.
Thus, amines 13a,b and amides 12a,b, longer and shorter homologues 12a-13a and 12b-13b exhibited the same hAChE inhibitory potency. In contrast, in the second series, the shorter homologue 18a was 8-fold more potent than the longer homologue 18b.
Indeed, 18a is the most potent hAChE inhibitor among all the novel benzohomoadamantane-chlorotacrine hybrids, so that the presence of an unsubstituted primary amino group at the benzohomoadamantane core and/or the presence of an amido linkage at the benzene ring with that particular linker length seem the most favorable substitution pattern for hAChE inhibition.
In contrast to hAChE inhibition, a broader range of IC50 values for hBChE inhibition was found for the novel hybrids, i.e. from 21 nM (18b) to 2.36 µM (12b), as well as more defined structure-activity relationships. The presence of basic amino group at the benzohomoadamantane core seems to be important for hBChE inhibition, with secondary amines 13 being 2-11-fold more potent than their amido counterparts 12, and with the primary amines 18, with a different disposition of the linker, being still more potent (2-10-fold more potent than amines 13 and 5-100-fold more potent than amides 12). Within the amines 13 and 18, a longer tether chain leads to a 5-23-fold greater hBChE inhibitory activity. Thus, the most potent hBChE inhibitors were hybrids 13b and 18b, which, with IC50 values of 210 and 21 nM, respectively, are 2-and 24-fold more potent than the parent 6-chlorotacrine. This supports the idea that the presence of the benzohomoadamantanamine moiety in these hybrids contributes positively to the interaction with the enzyme BChE.
NMDA receptor antagonistic activity of the novel benzohomoadamantanechlorotacrine hybrids
Apart from hAChE and hBChE, the NMDA receptor was the other primary biological target, which was pursued with the design of the benzohomoadamantane-chlorotacrine 13 hybrids. In particular, we inferred that the incorporation of the aminopolycyclic scaffold of the fluorobenzohomoadamantanamine 6, an NMDA receptor antagonist developed in our group [50] that is equipotent to memantine, into the structure of the hybrids should confer this additional activity.
To assess the NMDA antagonistic activity of the novel hybrids, we performed a functional assay based on measuring their effects on the increase in intracellular calcium evoked by NMDA (100 µM, in the presence of 10 µM glycine) in cultured rat CGN loaded with Fura-2 [49] . Memantine, 1, and fluorobenzohomoadamantanamine 6 were used as reference compounds for NMDA antagonism (Table 1) .
As previously mentioned, in all the described memantine-or amantadine-AChE inhibitor hybrids, the aminopolycyclic moiety is linked to the AChE inhibitor pharmacophore through its amino group. It has been described that alkylation of the amino group of memantine is detrimental for NMDA affinity and antagonistic activity, with monomethylation leading to a twofold reduced affinity and antagonistic activity, and dialkylation producing a 3-fold and 12-fold reduction of NMDA affinity and antagonistic activity, respectively [56] . A similar trend was also observed in some polycyclic amines that were developed in our group as NMDA receptor antagonists [47, 49, 50] , whereas the opposite trend was found in others [46, 48] . In line with our previous reports, alkylation of the bridgehead amino group of the benzohomoadamantane core in the novel hybrids may lead to reduced (13a vs 6, twofold reduction) or increased (13b vs 6, twofold increase) NMDA antagonistic activity, with the linker length seeming to play a role (the longer homologue 13b is 4fold more potent than the shorter counterpart 13a). Indeed, the most potent NMDA antagonist among the hybrids that are substituted at the bridgehead amino group, 13b, is equipotent to the most potent hybrid featuring an unsubstituted bridgehead primary amino group, 18a. Thus, it seems that this class of compounds can tolerate monoalkylation of the polycyclic amino group without losing NMDA antagonistic activity. However, acylation of this amino group seems to be clearly detrimental for NMDA antagonistic activity, with amides 12a and 12b being 2-and 9-fold less potent than amines 13a and 13b. These results are in agreement with those found in memantine-galantamine hybrids, where amido-linked hybrids displayed NMDA affinities 2-4-fold lower than those of the corresponding amines [42] . Therefore, the presence of a basic nitrogen atom at a bridgehead position of the polycyclic core seems to be favourable for NMDA antagonistic activity.
Overall, hybrids 13b and 18a are roughly twofold more potent NMDA antagonists than the parent benzohomoadamantanamine 6, which may be indicative of an additive effect of the chlorotacrine moiety in the interaction of the hybrids with these receptors.
Moreover, these novel hybrids are equipotent or slightly more potent (1.7-fold) than the NMDA antagonistic anti-Alzheimer drug memantine.
Evaluation of potential anti-amyloid activities of the novel benzohomoadamantanechlorotacrine hybrids
It has been shown that memantine inhibits in vitro the aggregation of human recombinant Aβ42 in a concentration-dependent manner, through NMDA receptorindependent mechanisms [62] . Also, chronic treatment with memantine leads to reduced brain levels of insoluble Aβ and soluble Aβ oligomers in several animal models of AD.
On the other hand, we have found that some classes of oligomethylene-linked 6chlorotacrine-based hybrids can inhibit in a cell-based assay the aggregation of the two amyloidogenic proteins involved in AD pathogenesis, i.e. Aβ and tau [52] . Additionally, other families of hybrid compounds featuring a huprine moiety, closely related to 6chlorotacrine, as AChE inhibitor pharmacophore, have been shown to inhibit in vitro BACE-1, the enzyme that catalyzes the first and rate-limiting step of Aβ production from the amyloid precursor protein (APP) [53, 63, 64] , with IC50 values ranging from nanomolar to low micromolar.
In the light of these findings, the presence in the novel hybrids of a 6-chlorotacrine unit and a benzohomoadamantanamine moiety, structurally related to memantine, prompted us to screen them for their potential inhibitory activity on Aβ and tau aggregation and BACE-1.
To assess the Aβ and tau anti-aggregating activity of the hybrids, we used a cell-based assay in intact Escherichia coli cells that overexpress either Aβ42, the most aggregation-prone and neurotoxic form of Aβ, or tau, which upon expression form insoluble inclusion bodies that can be stained with thioflavin S [65, 66] . When tested at an inhibitor concentration of 10 µM, low percentages of inhibition were found both for Aβ42 (up to 12%) and for tau (up to 23%) (Table 1) , so these compounds are weak antiaggregating compounds. We had found very similar results in other tacrine-and 6chlorotacrine-based hybrids that feature a cycloaliphatic ring as the second pharmacophoric moiety [51] , whereas much better anti-aggregating activities were found for 6-chlorotacrine-and huprine-based hybrids bearing as the second pharmacophore a polycyclic heteroaromatic system [52, 53, 67] . Thus, the presence of an extended aromatic system, apart from that of 6-chlorotacrine or huprine, seems to be a favourable structural requirement in this class of hybrid compounds for a good antiaggregating activity of Aβ42, tau, and other amyloidogenic protein involved in other major human disorders [67] .
Finally, we assessed the in vitro inhibitory activity of the novel hybrids towards human recombinant BACE-1, to find that they are essentially inactive or very weak inhibitors, with percentages of inhibition up to 18% at 5 µM. Even though the presence of a chlorotacrine unit, which should be mostly protonated in the acidic endosomal compartments where BACE-1 localizes, should enable a favourable salt bridge interaction with the aspartate residues of the catalytic dyad, the weak inhibitory activity of these hybrids should result from unfavourable secondary interactions of the benzohomoadamantane moiety within the large binding site of BACE-1.
Brain permeation
CNS drugs must be able to efficiently enter into the brain by crossing the blood-brain barrier (BBB). Hybrid compounds resulting from the pharmacophore combination approach tend to have rather large molecular weights, which might compromise their ability to cross biological membranes, including BBB [68, 69] .
However, an increasing number of structurally diverse anti-Alzheimer hybrid compounds with molecular weights over 500 have shown good brain permeability in in vivo studies in mice [22] . As a preliminary assessment of brain permeability, the novel benzohomoadamantane-chlorotacrine hybrids were subjected to the parallel artificial membrane permeation assay-BBB (PAMPA-BBB), a well-established in vitro model of passive transcellular permeation [70] . In this method, the permeability (Pe) of the target compounds through a lipid extract of porcine brain is determined using a 70:30 mixture hybrids of the first series, i.e. substituted at the bridgehead amino group, were predicted to be able to cross the BBB (Table 1) , which anticipates their ability to enter the brain and reach their different CNS targets. 
Conclusion
5-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-1-pentanol (9b)
A mixture of 6,9-dichloro-1,2,3,4-tetrahydroacridine, 8 (1.50 g, 5.95 mmol) and 5- 
5-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]pentyl methanesulfonate (10b)
A solution of alcohol 9b (368 mg, 1.15 mmol) and anhydrous Et3N (0.27 mL, 197 mg, 1.95 mmol) in dry CH2Cl2 (7 mL) was cooled at -10 º C with an ice / NaCl bath, and, then, treated dropwise with methanesulfonyl chloride (0.13 mL, 192 mg, 1.68 mmol).
The reaction mixture was stirred at -10 º C for 30 min and concentrated in vacuo. The residue was taken up in CH2Cl2 (20 mL), washed with 2N NaOH (3 × 15 mL), dried over anhydrous Na2SO4, and evaporated at reduced pressure, to afford mesylate 10b
(461 mg, quantitative yield) as a dark brown oil; Rf 0.72 (CH2Cl2 / MeOH / 50% aq. 
5-[(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]pentanenitrile (11b)
A mixture of 6-chlorotacrine, 7 (1.50 g, 6.45 mmol), finely powdered KOH (85% purity, 851 mg, 12.9 mmol), and 4 Å molecular sieves in dry DMSO (20 mL) was stirred, heating every 10 min with a heat gun for 1 h, and at room temperature for 1 20 additional h, and it was then treated with 5-bromovaleronitrile (0.9 mL, 1. 25 Chloro-1,2,3,4 -tetrahydroacridin-9-yl)amino]-N-(9-fluoro-7H- 5,6,8,9,10,11-hexahydro-5,9:7,11-dimethanobenzo[9] 5-[(6-Chloro-1,2,3,4 -tetrahydroacridin-9-yl)amino]-N-(9-fluoro-7H- 5,6,8,9,10,11-hexahydro-5,9:7,11-dimethanobenzo[9] annulen-7-yl)pentanamide (12b)
4-[(6-
This compound was prepared as described for 12a. Chloro-1,2,3,4 -tetrahydroacridin-9-yl)-N'- (9-fluoro-7H-5,6,8,9,10,11hexahydro-5,9:7,11-dimethanobenzo[9] annulen-7-yl)-1, 4 
N-(6-
-butanediamine (13a)
A solution of amide 12a (124 mg, 0.22 mmol) in dry THF (5 mL) was cooled to 0 º C with an ice bath, and then treated dropwise with BH3ꞏTHF (1M in THF, 0.87 mL, 0.87 mmol). The reaction mixture was stirred at room temperature overnight. The resulting mixture was cooled to 0 º C, and treated dropwise with MeOH (3 mL) and water (3 mL).
The organic phase was evaporated under reduced pressure, and the aqueous phase was 4.1.8. N-(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)-N'- (9-fluoro-7H-5,6,8,9,10,11hexahydro-5,9:7,11-dimethanobenzo[9] annulen-7-yl)-1, 5- 4.1.9. tert-Butyl (9-fluoro-7H-5,6,8,9,10,11-hexahydro-2-nitro-5,9:7,11dimethanobenzo[9] annulen-7-yl)carbamate (15) To a mixture of amine 14 [59] (496 mg, 1.79 mmol) and 2N NaOH (1.4 mL) in THF 4.1.10. tert-Butyl (2-amino-9-fluoro-7H-5,6,8,9,10,11-hexahydro-5,9:7,11dimethanobenzo[9] annulen-7-yl)carbamate (16) A suspension of the nitro derivative 15 (583 mg, 1.54 mmol) and PtO2 (48 mg, 0.12 mmol) in EtOH (100 mL) was hydrogenated at 1 atm of H2 at room temperature for 4 h. Hz, 1H, 4-H); 13 4.1.11. N-(7-Amino-9-fluoro-7H- 5,6,8,9,10,11-hexahydro-5,9:7,11- 
Evaluation of NMDA receptor antagonist activity
The functional assay for the determination of the antagonistic activity of the target compounds at the NMDA receptors was performed using primary cultures of rat cerebellar granule neurons, which were prepared following established protocols [49] .
Cells were grown on 10 mm poly-L-lysine coated glass cover slips and used for the experiments after 6-9 days in vitro. Cells were loaded with 6 μM Fura-2 AM (ThermoFisher-Invitrogen) for 30 min, and then, the coverslip was mounted on a quartz cuvette containing a Mg 2+ -free Locke-Hepes (LH) buffer using a special holder.
Measurements were performed using a Perkin Elmer LS-55 fluorescence spectrometer 
Evaluation of BACE-1 inhibitory activity
The inhibitory activity of the target compounds towards human recombinant BACE-1 (β-secretase, Invitrogen) was evaluated by employing the Panvera peptide as substrate [71] . 
Evaluation of Aβ42 and tau anti-aggregating activities
The inhibitory activities of the target compounds towards Aβ42 and tau aggregation were assessed using intact E. coli cells, as previously described [51, 65, 66] 
Evaluation of brain permeability: PAMPA-BBB assay
The brain permeability (Pe) of the target compounds was determined by the in vitro parallel artificial membrane permeability assay for blood-brain barrier penetration of Di et al. [70] , which employs a lipid extract of porcine brain membrane in PBS/EtOH 70:30. The assay was validated by comparison of the experimental and reported Pe values of a set of fourteen commercial drugs ( 
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